Citigroup’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-191,849
| Closed | -$3.02M | – | 5840 |
|
|
2024
Q1 | $3.02M | Buy |
191,849
+129,269
| +207% | +$1.99M | ﹤0.01% | 2088 |
|
|
2023
Q4 | $1.01M | Buy |
62,580
+2,000
| +3% | +$25.5K | ﹤0.01% | 2813 |
|
|
2023
Q3 | $771K | Sell |
60,580
-25,943
| -30% | -$358K | ﹤0.01% | 2721 |
|
|
2023
Q2 | $1.22M | Sell |
86,523
-105,281
| -55% | -$1.51M | ﹤0.01% | 2685 |
|
|
2023
Q1 | $2.96M | Buy |
191,804
+79,398
| +71% | +$1.33M | ﹤0.01% | 1769 |
|
|
2022
Q4 | $1.84M | Sell |
112,406
-75,812
| -40% | -$1.23M | ﹤0.01% | 2103 |
|
|
2022
Q3 | $3.48M | Buy |
188,218
+23,659
| +14% | +$371K | ﹤0.01% | 1763 |
|
|
2022
Q2 | $2.17M | Buy |
164,559
+94,099
| +134% | +$1.04M | ﹤0.01% | 2049 |
|
|
2022
Q1 | $653K | Sell |
70,460
-349,257
| -83% | -$2.97M | ﹤0.01% | 3320 |
|
|
2021
Q4 | $4.1M | Buy |
419,717
+338,209
| +415% | +$6.36M | ﹤0.01% | 1982 |
|
|
2021
Q3 | $2.77M | Sell |
81,508
-35,015
| -30% | -$1.12M | ﹤0.01% | 2275 |
|
|
2021
Q2 | $4.27M | Buy |
116,523
+16,655
| +17% | +$645K | ﹤0.01% | 2037 |
|
|
2021
Q1 | $4.48M | Buy |
99,868
+88,091
| +748% | +$4.1M | ﹤0.01% | 1861 |
|
|
2020
Q4 | $673K | Buy |
11,777
+5,496
| +88% | +$326K | ﹤0.01% | 3949 |
|
|
2020
Q3 | $321K | Sell |
6,281
-26,775
| -81% | -$1.31M | ﹤0.01% | 4230 |
|
|
2020
Q2 | $1.97M | Buy |
33,056
+953
| +3% | +$51K | ﹤0.01% | 2821 |
|
|
2020
Q1 | $1.32M | Buy |
32,103
+2,234
| +7% | +$124K | ﹤0.01% | 2892 |
|
|
2019
Q4 | $1.86M | Buy |
29,869
+6,368
| +27% | +$303K | ﹤0.01% | 3066 |
|
|
2019
Q3 | $798K | Sell |
23,501
-12,721
| -35% | -$377K | ﹤0.01% | 3884 |
|
|
2019
Q2 | $817K | Buy |
36,222
+19,849
| +121% | +$465K | ﹤0.01% | 3887 |
|
|
2019
Q1 | $380K | Sell |
16,373
-57,225
| -78% | -$1.5M | ﹤0.01% | 4480 |
|
|
2018
Q4 | $1.54M | Buy |
73,598
+48,850
| +197% | +$1.2M | ﹤0.01% | 2933 |
|
|
2018
Q3 | $959K | Buy |
24,748
+23,569
| +1,999% | +$871K | ﹤0.01% | 3546 |
|
|
2018
Q2 | $47K | Buy |
1,179
+51
| +5% | +$1.5K | ﹤0.01% | 6343 |
|
|
2018
Q1 | $23K | Buy |
1,128
+197
| +21% | +$4.99K | ﹤0.01% | 6681 |
|
|
2017
Q4 | $21K | Buy |
+931
| New | +$18.2K | ﹤0.01% | 6720 |
|
Other funds holding DCPH
Citigroup's DCPH Position: Q2 2024 in Review
Citigroup sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 191,849 shares — an estimated $3.02M sold.
Citigroup first reported a position in DCPH in Q4 2017 and held it in 26 quarters. The position peaked at $4.48M in Q1 2021. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Citigroup reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Citigroup sold 191,849 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $3.02M.
- Citigroup first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 26 quarters.
- Citigroup's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $4.48M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.